Global Ganja Report

A new product is being plugged as containing CBD derived from humulus—that is, hops, the buds used as a bittering agent in beer. Some of the media hype has implied that this novel origin gets around the US federal stricture on the cannabinoid. But experts raise a skeptical eyebrow at the claim of hops-derived CBD. And in any event, the federal stricture is on the cannabinoid itself, regardless of how it is derived. 

California health authorities dealt a blow to the burgeoning CBD business by banning preparations of the cannabinoid derived from industrial hemp rather than psychoactive cannabis. The diktat adds to the legal confusion around CBD, and highlights the need for greater clarity from the competent authorities at both the state and federal level.

A federal appeals court has turned down a challenge by the cannabis industry to the DEA's official finding that CBD is a controlled substance. But questions about whether CBD should be treated as a controlled substance remain pending at the state level.

A judge for the US District Court for the Southern District of New York on Feb. 26 dismissed a lawsuit challenging the Schedule I classification for cannabis under the Controlled Substances Act. Judge Alvin Hellerstein granted the government's motion to dismiss because the plaintiffs failed to exhaust all administrative remedies prior to initiating the suit. The "exhaustion rule" requires "that parties exhaust prescribed administrative remedies before seeking relief from federal courts."

It has been a long, slow ride for patients hoping to get access to medical marijuana in the Lone Star state—and then just special strains of low-THC cannabis, and only for those suffering from "intractable epilepsy." Three dispensaries are hoping to get final approval from Texas authorities to start cultivating next month. Of course, it will be several more months before they can actually begin distributing—and then ambiguities in the law may mean further delays. Activists and lawmakers are pushing both to clear things up and expand the scope of the program.

A 29-year-old man believed to be the godson of Mexican narco lord Joaquin “El Chapo” Guzmán was indicted on drug  charges in a San Diego federal court Aug. 7. Damaso López Serrano AKA "Mini Lic" was charged with smuggling unspecified quantities of methamphetamine, cocaine and heroin. He'd turned himself in to US border agents several days earlier, and is said to be the highest-ranking Mexican kingpin ever to surrender in the territory of the United States.

Hemp Business Journal reports that products infused with CBD oil are leading growth in hermp-derived products sold in the United States generally, which in 2016 had a collective retail value of $688 million. This figure represents a five year 22% compound annual growth rate (CAGR). Joining more traditional products such as shelled seed, protein powder, soaps and lotions, are growing lines of medicinal preparations such as CBD edibles. Hemp-derived cannabidiol (CBD) accounted for $130 million in sales last year.

Oops, he did it again. Acting Drug Enforcement Administration chief Chuck Rosenberg reiterated his oft-voiced opinion on May 25 that "marijuana is not medicine." The Washington Examiner reports that he told an audience at a clinic in Cleveland: "If it turns out that there is something in smoked marijuana that helps people, that's awesome. I will be the last person to stand in the way of that... But let's run it through the Food and Drug Administration process, and let's stick to the science on it."